A monthly figure in this market is a bundle, and the bundle is not standardized. Six things might be inside it or beside it: the consultation, the injection supplies, shipping, lab work, provider messaging between visits, and whatever happens to the price when the dose goes up. Across the sellers written up here, the median one settles exactly one of those six.
What gets specified, and how often
Counting a line item as resolved whenever the seller’s own copy settles it either way — included, or charged separately — the order across the 257 sellers written up when this was counted runs: shipping 68, what a dose increase costs 61, the consultation 53, injection supplies 33, lab work 19, provider messaging 17. The mean seller resolves 0.98 items of six. 105 of 257 — 40.9% — resolve none of them. Five resolve four or more. Not one resolves all six.
The ordering is the finding. Shipping is the item at the top, and shipping is the smallest item on the list: a few dollars of cold-chain postage that a seller can absorb and advertise as free. Lab work sits near the bottom, and lab work is the item a cash-paying buyer can be billed hundreds of dollars for — billed by somebody else, which is precisely why a seller has no commercial reason to mention it. What a monthly figure buys is stated most precisely where stating it costs the seller least.
Shipping is settled most often and decides least
Sixty-eight of 257 settle shipping, which makes it the best-answered line on the list and the one least likely to change a purchase decision. It is also the item where a settled answer covers the narrowest ground. “Free shipping” resolves who pays the carrier. It does not resolve how fast the package moves, whether it travels with a cold pack, what happens to a vial that arrives warm, or who absorbs the replacement — and a peptide preparation that has been sitting in a delivery vehicle in August is a different question from a postage line. Fifteen sellers here attach a dollar figure to shipping rather than folding it in, which at least makes the two models distinguishable.
Labs: the question that is usually not answered
The pattern is sharpest where the question has been put directly. Across the 102 sellers here whose bloodwork status has been examined, 84 do not state it at all, 10 state that labs are an extra cost, and 8 state that they are included. A baseline panel is standard practice before starting an incretin and is often repeated during titration, so a buyer comparing two identical monthly figures where one includes labs and the other does not is comparing two different products — and in 84 of 102 cases the information needed to tell them apart is not on the page.
Injection supplies fall in the same category and are resolved by 33 of 257. A compounded vial is not a pen: it needs syringes, needles, alcohol preparation and a sharps container, which a buyer may be expected to source independently. What that actually involves is set out in the supplies article, and the shipping question that ranks at the top of the list has its own complications, covered in the cold-chain article.
The consultation, and the two ways it is priced
Fifty-three of 257 settle what happens to the clinical visit, and they split almost evenly between two incompatible models. In one the consultation is inside the monthly figure and no separate charge exists. In the other it is a line of its own — a screening fee, a professional services charge, a deposit taken at booking, or a membership that buys the clinician and leaves the medication to be billed on top. Both are legitimate. They are not comparable, and a buyer reading two monthly figures has no way to tell which model produced either unless the seller says.
The second model carries a wrinkle that only appears at the exit. Where the consultation is billed separately it is often billed first — before a clinician has ruled on eligibility — and where it is billed first it is frequently the one component that does not come back if the answer is no, on the reasoning that the screening was performed. That is a coherent position and it means the advertised monthly figure and the smallest amount a buyer can spend are different numbers even for someone who never receives a prescription. How that compares with paying a clinic directly is worked through in the telehealth-versus-clinic article.
Provider messaging is the least-specified item of the six, settled by 17 of 257, and it is the one whose absence is easiest to misread. Dose adjustment on an incretin is a conversation, not an event: nausea at a step, a plateau, a decision to hold at a dose rather than climb. A plan that includes messaging and a plan that charges per visit will diverge most for exactly the buyers who need the most contact, and in 240 of the 257 cases here the figure on the card does not distinguish them.
The dose axis, where the money actually moves
One line item can change the annual bill more than the other five combined. A semaglutide course that begins at 0.25 mg weekly and maintains at 2.5 mg multiplies the drug in the vial tenfold; tirzepatide from 2.5 mg to 15 mg multiplies it sixfold. Whether that multiplication reaches the buyer’s card is the single most consequential thing a monthly figure can specify, and it is settled for 184 of the 474 sellers here — 38.6%.
Among those 184, 148 hold one price at every dose and 36 re-price as the dose climbs. That is the reversal for anyone arriving from the brand market, where a higher dose is a different NDC at a different price: in this market, where the answer exists at all, four sellers in five do not raise the bill at 2.5 mg. The assumption is backwards. It is also unavailable for the other 293 sellers, who have stated no policy in either direction, so a flat price cannot be assumed by default either. The titration ladder itself, and where each step lands, is in the titration article, and the sellers who commit to one rate across it are collected on the flat-pricing board.
There is a second half to the dose problem, and it is worse. Of the 168 sellers here examined on the question, 118 publish no milligram figure anywhere on the product page against 50 that do. A price with no dose attached cannot be compared to any other price, flat or otherwise, because the unit is undefined — and a flat rate covering an unstated dose range is a promise about a quantity nobody has written down. What the bill looks like once titration finishes is worked through in the maintenance-cost article.
What is in the vial is a pricing question too
Two monthly figures are only comparable if the preparations behind them are. In a secret-shopper study of 75 weight-loss clinics and medical spas across two states, conducted from August to October 2025, 42 — 56.0% — offered a compounded GLP-1 combined with B vitamins, and 7 offered an oral formulation.[1] The study also traced the products to 23 compounding facilities, of which 4 of 21 were not licensed to perform sterile compounding and 3 of 22 had been subject to state-level disciplinary action since 2023. A combination product and a single-agent vial are different goods at whatever price each carries.
The identity of the preparer is a related blank: across the 239 sellers here examined on it, 45 name the compounding pharmacy and the rest describe it only in general terms. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before dispensing, so the facility is the whole of the quality question, and the questions worth asking about it are listed in the vetting article.
What this does not establish
Coverage is not census, and every count above is a floor rather than a measurement. Of the 474 sellers here, 257 have a write-up, and a line item recorded as unresolved may be unstated on the seller’s site or may simply not have been adjudicated. The honest reading of “105 sellers resolve none of the six” is that 105 write-ups record no answer, not that 105 sellers publish nothing — and an absence of a recorded answer is an absence of examination.
Nor is a specified bundle a good bundle. A seller stating plainly that labs are an extra cost has been more useful than one that says nothing, and has not thereby become cheaper. The practical output is four questions with numeric answers, which any seller can give in writing before a card is entered: what does the figure cover at the starting dose, what does it cover at the maintenance dose, what am I billed separately for, and in how many milligrams is the answer denominated. Turning those answers into an annual figure is what the cost calculator is for.